Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number

被引:4
作者
Tas, Faruk [1 ]
Erturk, Kayhan [2 ]
机构
[1] Istanbul Univ, Inst Oncol, TR-34390 Istanbul, Turkey
[2] Koc Univ, Dept Med Oncol, Istanbul, Turkey
关键词
melanoma; stage III; mitotic rate; node-positive; AMERICAN JOINT COMMITTEE;
D O I
10.1093/jjco/hyab031
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Stage III melanoma is a heterogenous disease, and the number of tumor-involved lymph nodes is the most significantly unfavorable prognostic indicator for relapse and outcome. The aim of this study is to investigate the possible effects of the various clinicopathological factors on the course of node-positive stage III disease. Methods: A total of 389 node-positive stage III cutaneous melanomas were included in the study and analyzed retrospectively. All underwent pathological nodal staging by sentinel lymph node biopsy or elective lymph node dissection. Results: The group was male-dominant (59%) and the median age was 50 years. The largest group of patients was N1 (n = 221, 56.8%) followed by N2 (n = 105, 27.0%) and N3 (n = 63, 16.2%). N1 melanomas were less frequently associated with relapses than melanomas with multiple lymph node metastases (P = 0.05). The 5-year relapse-free survival rate was 37.9%. The melanomas with multiple lymph nodes metastases (P = 0.01), higher mitotic rate (P = 0.005) and ulceration (P = 0.02) had worse RFS. In the multivariate analysis only the significances of the N2-N3 stage (P = 0.016) and higher mitosis (P = 0.012) persisted. The severe lymph node metastasis (N2-N3) was associated with a higher mortality rate in comparison with the single nodal involvement (P = 0.05). The 5-year overall survival rate was 52.1%. Presence of relapse (P = 0.0001), higher mitotic rate (P = 0.03) and N2-N3 stage (P = 0.04) were inversely correlated with the overall survival. When relapse was included in the multivariate analysis, it was the only significant prognostic factor on survival (P = 0.0001), whereas mitosis became the only significant factor on survival with the exclusion of relapse from the multivariate analysis (P = 0.031). Conclusion: In node-positive stage III melanoma, tumor mitotic rate might be just as significant a prognostic indicator as the metastatic lymph node number.
引用
收藏
页码:873 / 878
页数:6
相关论文
共 7 条
  • [1] Update on the Melanoma Staging System: The Importance of Sentinel Node Staging and Primary Tumor Mitotic Rate
    Balch, Charles M.
    Gershenwald, Jeffrey E.
    Soong, Seng-Jaw
    Thompson, John F.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (04) : 379 - 385
  • [2] Tumor mitotic rate is an independent predictor of survival for nonmetastatic melanoma
    Evans, Jessica L.
    Vidri, Roberto J.
    MacGillivray, Dougald C.
    Fitzgerald, Timothy L.
    [J]. SURGERY, 2018, 164 (03) : 589 - 593
  • [3] Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
    Gershenwald, Jeffrey E.
    Scolyer, Richard A.
    Hess, Kenneth R.
    Sondak, Vernon K.
    Long, Georgina V.
    Ross, Merrick I.
    Lazar, Alexander J.
    Faries, Mark B.
    Kirkwood, John M.
    McArthur, Grant A.
    Haydu, Lauren E.
    Eggermont, Alexander M. M.
    Flaherty, Keith T.
    Balch, Charles M.
    Thompson, John F.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (06) : 472 - 492
  • [4] Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma
    Haydu, Lauren E.
    Lo, Serigne N.
    McQuade, Jennifer L.
    Amaria, Rodabe N.
    Wargo, Jennifer
    Ross, Merrick, I
    Cormier, Janice N.
    Lucci, Anthony
    Lee, Jeffrey E.
    Ferguson, Sherise D.
    Saw, Robyn P. M.
    Spillane, Andrew J.
    Shannon, Kerwin F.
    Stretch, Jonathan R.
    Hwu, Patrick
    Patel, Sapna P.
    Diab, Adi
    Wong, Michael K. K.
    Oliva, Isabella C. Glitza
    Tawbi, Hussein
    Carlino, Matteo S.
    Menzies, Alexander M.
    Long, Georgina, V
    Lazar, Alexander J.
    Tetzlaff, Michael T.
    Scolyer, Richard A.
    Gershenwald, Jeffrey E.
    Thompson, John F.
    Davies, Michael A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (13) : 1429 - +
  • [5] Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review
    Miller, Rachael
    Walker, Sophie
    Shui, Irene
    Brandtmuller, Agnes
    Cadwell, Kevin
    Scherrer, Emilie
    [J]. MELANOMA MANAGEMENT, 2020, 7 (01) : 39 - 52
  • [6] Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21590, 10.3322/caac.21601]
  • [7] Primary tumour ulceration in cutaneous melanoma: its role on TNM stages
    Tas, Faruk
    Erturk, Kayhan
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (02) : 192 - 198